Medpace Holdings Inc. posted stronger-than-expected second-quarter results as demand for its contract research services accelerated. Revenue rose 14.2% from a year earlier to $603.3 million, while GAAP net income reached $90.3 million, or $3.10 a share, topping the roughly $2.98 analysts had anticipated. EBITDA climbed 16.2% to $130.5 million, producing a 21.6% margin. The Cincinnati-based company booked a record $620.5 million in new business awards, yielding a book-to-bill ratio of 1.03. Backlog edged down 1.8% to $2.87 billion. During the quarter Medpace repurchased 1.75 million shares for $518.5 million, leaving $826.3 million available under its authorization. Citing the upbeat momentum, management lifted full-year 2025 guidance. Revenue is now projected at $2.42 billion to $2.52 billion, implying up to 19.5% growth, while GAAP earnings are seen at $13.76 to $14.53 per diluted share. The results and higher outlook sent Medpace shares surging about 40% in after-hours trading, snapping a period of range-bound performance.